KTTA סך נכסי הפעילות העסקית Pasithea

The development of Pasithea Therapeutics (KTTA) relies on successes in creating drugs for CNS pathologies and substantial capital, although expansion is hindered by intense pressure from resource-rich pharma behemoths. This price chart illustrates total assets at 34.36. Meanwhile, the brand maintains moderate appeal among physicians and cautious optimism among specialized investors.

Total assets represent the aggregate value of all corporate resources, calculated inversely via ROA to eliminate market noise, allowing GURU.Markets investors to track capital dynamics across Pasithea Therapeutics (KTTA) assets based on ROA and assess the risk of capital erosion, particularly now that the stabilized management of Pasithea Therapeutics must maintain strict financial discipline while implementing clinical programs.